0VZ7 Stock Overview
Operates in the pharmaceutical sector in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
HAEMATO AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.99 |
| 52 Week High | €28.00 |
| 52 Week Low | €14.99 |
| Beta | 1.29 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -43.87% |
| 5 Year Change | n/a |
| Change since IPO | -73.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VZ7 | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -1.4% |
| 1Y | n/a | -24.0% | 4.6% |
Return vs Industry: Insufficient data to determine how 0VZ7 performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how 0VZ7 performed against the UK Market.
Price Volatility
| 0VZ7 volatility | |
|---|---|
| 0VZ7 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0VZ7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0VZ7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 76 | Patrick Brenske | www.haemato.ag |
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements.
HAEMATO AG Fundamentals Summary
| 0VZ7 fundamental statistics | |
|---|---|
| Market cap | €87.82m |
| Earnings (TTM) | €9.61m |
| Revenue (TTM) | €260.81m |
9.1x
P/E Ratio0.3x
P/S RatioIs 0VZ7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VZ7 income statement (TTM) | |
|---|---|
| Revenue | €260.81m |
| Cost of Revenue | €241.08m |
| Gross Profit | €19.73m |
| Other Expenses | €10.12m |
| Earnings | €9.61m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.84 |
| Gross Margin | 7.56% |
| Net Profit Margin | 3.68% |
| Debt/Equity Ratio | 0.2% |
How did 0VZ7 perform over the long term?
See historical performance and comparisonDividends
7.1%
Current Dividend Yield64%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/08 10:51 |
| End of Day Share Price | 2024/04/10 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HAEMATO AG is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Acklin | First Berlin Equity Research GmbH |
| Cosmin Filker | GBC AG |
| Christian Ehmann | Warburg Research GmbH |